Stockreport

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Polyrizon Ltd. - Ordinary Shares  (PLRZ) 
PDF Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary ME [Read more]